Heptaminol
Structural formula | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Structural formula without stereochemistry | |||||||||||||
General | |||||||||||||
Non-proprietary name | Heptaminol | ||||||||||||
other names | |||||||||||||
Molecular formula | C 8 H 19 NO | ||||||||||||
Brief description |
colorless liquid (base, racemate) |
||||||||||||
External identifiers / databases | |||||||||||||
|
|||||||||||||
Drug information | |||||||||||||
ATC code | |||||||||||||
Drug class | |||||||||||||
properties | |||||||||||||
Molar mass | |||||||||||||
Melting point |
<25 ° C (base, racemate) |
||||||||||||
boiling point | |||||||||||||
safety instructions | |||||||||||||
|
|||||||||||||
Toxicological data | |||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Heptaminol is a 1: 1 mixture ( racemate ) of two enantiomeric chemical compounds from the group of amino alcohols , which is used as a drug in the group of sympathomimetics in the treatment of cardiovascular diseases . Heptaminol was developed by Bilhuber and patented in 1948. The racemate of the drug is used as a more water-soluble hydrochloride and as an ester acefylline-heptaminol with acefylline (1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-acetic acid).
Clinical information
Heptaminol is used for hypotension , "old age heart", as well as for accompanying therapy with digitalism medication . Usually, a dose of 150 mg three times a day ( orally ) or 200 mg twice a day as a sustained- release formulation.
Pharmacological properties
Heptaminol has an indirect sympathomimetic effect by inhibiting the reuptake of noradrenaline in the synaptic gap . Heptaminol has a plasma half-life from 2.5 to 2.7 hours and is unchanged in the urine excreted .
Other Information
Heptaminol is used for doping purposes. It is listed on the World Anti-Doping Agency (WADA) list as a stimulant that is prohibited during athletic competitions.
Trade names
- Heptylon
- Generics
Individual evidence
- ↑ a b c d e f g Entry on heptaminol. In: Römpp Online . Georg Thieme Verlag, accessed on July 12, 2011.
- ↑ a b Entry on heptaminol in the ChemIDplus database of the United States National Library of Medicine (NLM) .
- ↑ harmonized classification for this substance . A labeling of heptaminol in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on March 27, 2020, is reproduced from a self-classification by the distributor . There is not yet a
- ^ H. Grobecker: On the mode of action of heptaminol . In: Naunyn-Schmiedeberg's Archives of Pharmacology . 266, No. 4-5, 1970, pp. 339-340. doi : 10.1007 / BF00997979 .
- ^ F. Kees: Bioavailability studies of heptaminol in healthy volunteers . In: drug research . 37, No. 10, 1987, pp. 1182-1185.
- ↑ The World Anti-Doping Code: The 2009 Prohibited List, International Standard , p. 7 ( Memento of July 19, 2014 in the Internet Archive ) (PDF; 177 kB).